Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A

Chao Yang; Dan Li; Shaohong Zang; Lei Zhang; Zhangfeng Zhong; Yingtang Zhou

doi:10.3389/fphar.2022.955218

Mechanisms of carcinogenic activity triggered by lysine-specific demethylase 1A

Front Pharmacol. 2022 Jul 19:13:955218. doi: 10.3389/fphar.2022.955218. eCollection 2022.

Authors

Chao Yang¹, Dan Li², Shaohong Zang¹, Lei Zhang³, Zhangfeng Zhong⁴, Yingtang Zhou¹

Affiliations

¹ National Engineering Research Center for Marine Aquaculture, Institute of Innovation and Application, Zhejiang Ocean University, Zhoushan, China.
² State Key Laboratory of Southwestern Chinese Medicine Resource, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
³ Department of Chemical Engineering, Waterloo Institute for Nanotechnology, University of Waterloo, Waterloo, ON, Canada.
⁴ Macau Centre for Research and Development in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao SAR, China.

Abstract

Epigenetics has emerged as a prime focus area in the field of cancer research. Lysine-specific demethylase 1A (LSD1), the first discovered histone demethylase, is mainly responsible for catalysing demethylation of histone 3 lysine 4 (H3K4) and H3K9 to activate or inhibit gene transcription. LSD1 is abnormally expressed in various cancers and participates in cancer proliferation, apoptosis, metastasis, invasion, drug resistance and other processes by interacting with regulatory factors. Therefore, it may serve as a potential therapeutic target for cancer. This review summarises the major oncogenic mechanisms mediated by LSD1 and provides a reference for developing novel and efficient anticancer strategies targeting LSD1.

Keywords: LSD1; anticancer activity; demethylation; epigenetics; histone modifications; lysine methylation; signaling pathway; targets.

Publication types

Review